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Background: Long QT syndrome (LQTS) is an inherited arrhythmic disorder characterised by prolongation of the
QT interval on ECG, presence of syncope and sudden death. The symptoms in LQTS patients are highly variable,
and genotype influences the clinical course. This study aims to report the spectrum of LQTS mutations in a
Swedish cohort.
Methods: Between March 2006 and October 2009, two hundred, unrelated index cases were referred to the
Department of Clinical Genetics, Umeå University Hospital, Sweden, for LQTS genetic testing. We scanned five of
the LQTS-susceptibility genes (KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2) for mutations by DHPLC and/or
sequencing. We applied MLPA to detect large deletions or duplications in the KCNQ1, KCNH2, SCN5A, KCNE1, and
KCNE2 genes. Furthermore, the gene RYR2 was screened in 36 selected LQTS genotype-negative patients to detect
cases with the clinically overlapping disease catecholaminergic polymorphic ventricular tachycardia (CPVT).
Results: In total, a disease-causing mutation was identified in 103 of the 200 (52%) index cases. Of these, altered
exon copy numbers in the KCNH2 gene accounted for 2% of the mutations, whereas a RYR2 mutation accounted
for 3% of the mutations. The genotype-positive cases stemmed from 64 distinct mutations, of which 28% were
novel to this cohort. The majority of the distinct mutations were found in a single case (80%), whereas 20% of the
mutations were observed more than once. Two founder mutations, KCNQ1 p.Y111C and KCNQ1 p.R518*, accounted
for 25% of the genotype-positive index cases. Genetic cascade screening of 481 relatives to the 103 index cases
with an identified mutation revealed 41% mutation carriers who were at risk of cardiac events such as syncope or
sudden unexpected death.
Conclusion: In this cohort of Swedish index cases with suspected LQTS, a disease-causing mutation was identified
in 52% of the referred patients. Copy number variations explained 2% of the mutations and 3 of 36 selected cases
(8%) harboured a mutation in the RYR2 gene. The mutation panorama is characterised by founder mutations (25%),
even so, this cohort increases the amount of known LQTS-associated mutations, as approximately one-third (28%)
of the detected mutations were unique.
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Long QT syndrome (LQTS) is an autosomal dominant
inherited arrhythmogenic disease and a significant cause
of sudden cardiac death (SCD), usually in young and
otherwise healthy individuals. LQTS is characterised by
delayed ventricular repolarisation, seen as prolongation
of the QT-interval on the electrocardiogram (ECG),
which predisposes to Torsade-de-Pointes (TdP) and sub-
sequent sudden death by ventricular fibrillation [1,2].
TdP or ventricular tachyarrhythmia is often self-
terminating and presents as syncope with loss of con-
sciousness, the most frequent symptom of LQTS. The
phenotype is highly variable in expressivity and incom-
plete in penetrance [3]. Although the majority of LQTS
patients show a diagnostic prolongation of the QT-
interval on resting ECG, a normal ECG with a normal
QTc is not enough to rule out LQTS, since up to ap-
proximately 40% of the patients may present with a nor-
mal QT-interval. A LQTS mutation carrier without
prolonged QTc has a 10% risk of major cardiac events
by the age of 40 years when left without treatment [4].
Cardiac events are often prompted by physical activity
or by intense emotion or stress, but can also occur at
rest or during sleep [5,6]. Exercise-induced syncope can
also be caused by another inherited ion-channel disease,
named catecholaminergic polymorphic ventricular
tachycardia (CPVT), which is characterised by cardiac
electrical instability exacerbated by acute activation of
the adrenergic nervous system [7]. Some patients sus-
pected to have LQTS might actually have CPVT, since
there is a clinical overlap between these disorders [8,9].
The prevalence of LQTS has been estimated to 1/
2,000 in the population [10]. To date, 13 different genes
have been associated with LQTS, all encoding subunits
of cardiac ion-channels (K+, Na+ or Ca2+) or ion-channel
regulatory proteins [11]. More than 90% of the muta-
tions are found in five of the genes (KCNQ1, KCNH2,
SCN5A, KCNE1 and KCNE2), and mutation analysis of
these five LQTS-causing genes reveals a mutation in
about 75% of patients with a clinical diagnosis of LQTS
[8,12-15]. Typically, the disease-causing mutation is
a missense mutation that is unique for the family,
although founder mutations have been described in dif-
ferent, relatively isolated populations [16-18]. The occur-
rence of families with compound heterozygote mutations
or apparent digenic inheritance, as well as rare variants of
uncertain significance (VUS), further complicates the
genetics of LQTS [19,20].
First-degree relatives of a mutation carrier are at 50%
risk of carrying the mutation [15], and familial cascade
screening should thus be offered immediately to all fam-
ilies with a disease-causing mutation. Identifying add-
itional family members at risk for the condition is of
critical importance since they can get preventivetreatment, thus decreasing the risk of fatal cardiac
events. Here, we examine the spectrum of mutations in




Between March 2006 and October 2009, a total of 200
unrelated index cases (138 females; 62 males) were re-
ferred to the Department of Clinical Genetics, Umeå
University Hospital, Sweden, for LQTS genetic testing as
part of ordinary health care. Clinical data, including 12-
lead ECG, personal history of syncope, treatment with
beta-blockers, and family history, was retrospectively
collected from referring physicians. The mean age of the
200 index patients at the time of ascertainment was 33
(± 20) years. Corrected QT measurements were obtained
from 125 index cases by two different investigators
(UBD, SJ) who were blinded to genetic status and the
identity of the patient. QT interval was obtained from
12-lead ECG and corrected for heart rate using Bazett’s
formula. Additionally, 12 QTc measurements of index
cases were obtained from referring clinicians.
For the interpretation of novel missense variants, clin-
ical data and blood samples from family members (both
parents and siblings when available) were collected to
look for co-segregation between the sequence variant
and the disease in the family. Pedigrees were constructed
using Cyrillic 2.1 (Cyrillic Software, Oxfordshire, United
Kingdom).
The Regional Ethical Review Board of Umeå Univer-
sity approved this study. Data for continuous variables
are presented as mean, standard deviations (SD) and/or
range. The Mann–Whitney test was used for compari-
son of QTc, and parametric tests were used for compari-
son of normally distributed variables. Statistical analysis
was performed using GraphPad Prism 5.0 (GraphPad
Software, Inc. USA).
Mutation analysis
DNA was extracted from peripheral blood lymphocytes
using a standard salting-out method. Genomic DNA of
the 200 index cases were analysed for mutations in all
protein-coding exons and their flanking splice site regions
of the genes KCNQ1 (NM_000218.2 and NM_181798.1),
KCNH2 (NM_000238.2 and NM_172057.1), SCN5A
(NM_198056.1), KCNE1 (NM_000219.2), and KCNE2
(NM_172201.1) using PCR, denaturing high-performance
liquid chromatography (DHPLC; WAVE, Transgenomic,
Omaha, Neb), and/or bi-directional sequencing on the
CEQ 8000 (Beckman Coulter, Fullerton, CA, USA) or the
ABI 3100 Genetic Analyzer (Applied Biosystems, Foster
City, CA, USA). All primers were checked for absence of
SNPs to avoid problems with allelic dropout. All five
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a mutation had been identified in one of the genes. Briefly,
samples were PCR-amplified by standard methods (primer
sequences available on request) and then analysed by
DHPLC at one or more temperatures based on the melt-
ing profile of the fragment, as determined by Navigator
Software version 2.1.0 (Transgenomic). Chromatograms
were subjectively grouped, depending on the differences
in the profile from normal and known polymorphic var-
iants. Where abnormal patterns of elution were identified,
the fragments were sequenced for detection of rare var-
iants. To ensure relevance, all likely pathogenic changes
were re-amplified using a different dilution of the same
sample.
For cascade screening of relatives, mutation analysis
was performed by sequencing as described above, or by
directed mutation analysis with MGB probes using the
TaqMan 7000 (Applied Biosystems, Foster City, CA,
USA). In the latter case, a positive and a genotype- nega-
tive familial control was included in each analysis.
All samples were analysed for large deletions or
duplications using multiplex ligation-dependent probe
amplification (MLPA) with the SALSA P114-A2 kit
(MRC-Holland), which covers exons 1B, 1–4, 6–13 and
15–16 for KCNQ1 (NM_000218.2 and NM_181798.1),
exons 1B, 1–4, 6, 9–10 and 14 for KCNH2 (NM_000238.2
and NM_172057.1), exons 1–2 for KCNE2 (NM_172201.1),
exons 2–4 for KCNE1 (NM_000219.2), and exons 2, 4,
25 and 27 for SCN5A (NM_198056.1). Thirty-six of the
LQTS genotype-negative index cases were also analysed
for mutations in 23 of the 105 functionally most import-
ant exons (8–15, 44–50, 83, 88–105) of the gene RYR2
(NM_001035.2). These cases were selected for RYR2
screening based on a history of sudden unexpected
death (n=1), aborted cardiac arrest (n=10), ICD treat-
ment (n=3), documented arrhythmia (n=3), and/or syn-
cope (n=31) and/or a family history of SCD (n=11).
Defining mutation status
Sequences were evaluated using the software
Sequencher™ 4.9 (Gene Codes Corporation, MI, USA).
All identified LQTS-associated mutations and other var-
iants were denoted using nomenclature recommended
by Human Genome Variation Society (HGVS) [21]. To
be considered as a LQTS-causing mutation, the variant
must disrupt or change either the open reading frame
(i.e., missense, nonsense, insertion/deletion, or frame
shift mutations) or the conserved splice recognition
sequences (the first two intronic nucleotides flanking the
exon). Variants that did not change the open reading
frame (i.e. synonymous) and intronic variants located
outside of the splice recognition sequence (i.e. beyond
IVS-2 or IVS+2) were not considered unless an effect
on splicing could be predicted using bioinformatictools (SpliceSiteFinder, MaxEntScan, NNSPLICE and
GeneSplicer).
In addition, variants that were previously described in
healthy individuals and in NCBI dbSNP as common or
rare single nucleotide polymorphisms, such as KCNQ1
p.P448R, KCNE1 p.D85N, SCN5A p.H558R, or SCN5A
p.A572D, were not considered to be a pathogenic muta-
tion. In silico predictions were made for all putative
mutations using the Alamut software version 1.5 (Inter-
active Biosoftware, Rouen, France). The Alamut software
assists in evaluation of missense variants by compiling
output from a number of bioinformatic prediction tools,
including Polymorphism Phenotyping (PolyPhen), Sort-
ing Intolerant From Tolerant (SIFT) and Align Gran-
tham Variation and Grantham Deviation (Align-GVGD)
[22-24].
Novel missense variants were considered mutations
only if an effect on the protein could be predicted using
bioinformatic tools, and/or if they were absent from 100
control individuals, from the same population, and/or if
they co-segregated with affected family members. For all
novel missense variants, phylogenetic conservation was
evaluated using the Alamut software.
Results
Subjects and clinical phenotype
DNA for mutation screening was available from 200
index patients (138 females; 62 male) referred for mo-
lecular genetic screening of long QT-syndrome to the
Department of Clinical Genetics, Umeå University Hos-
pital, Sweden. Referrals came from all six health care
regions, 44 cases from the North health care region, 36
from Uppsala-Örebro, 54 from Stockholm, 43 from the
West, 17 from the Southeast, and 6 cases from the South
health care region. Questionnaires with clinical data were
received for 125 of the index patients from referring phy-
sicians. The demographics (age, sex, QTc, symptoms,
family history, and treatment with beta-blockers) of all
available patients are summarised in Table 1.
The average age at ascertainment was 33 ±20 years
(range 13 days to 79 years). An ECG was available for
137 (68%) of the index cases. The average QTc among
all available index patients was 463 ms (± 44). The aver-
age QTc was 479 ms (± 37) among KCNQ1 mutation
carriers, 472 ms (± 30) among KCNH2 mutation car-
riers, and 505 ms (± 66) among SCN5A mutation car-
riers. The average QTc among index cases without an
identified mutation was 445 ms (± 41) (Table 1). Al-
though there was no significant difference in QTc-
interval between LQT1-3 mutation carriers, there was a
significant difference in QTc interval between mutation
carriers and index cases without an identified mutation
(Figure 1). Among the genotype-positive cases there
were 33 individuals with a QTc ≥480 ms, and among the
Table 1 Demographics of all available, unrelated index cases referred for molecular genetic testing regarding Long QT


























































































The numbers in parenthesis refers to the number of cases in each category. No percentages are calculated if there are less than 10 cases.
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the patients with a prolonged QT interval, 77% carried a
LQTS mutation whereas 23% had no mutation. Further-
more, 38% of the patients with a normal QT interval
carried a mutation, whereas 62% had no mutation.
Among subjects selected for RYR2 screening (n=36) the
average QTc was 432 ms (range 347–477 ms), of which
five of them had a QTc prolongation >460 ms (25 avail-











Figure 1 Graphic illustration of the difference between QTc
among mutation carriers (KCNQ1, KCNH2 and SCN5A) compared
with index cases in which no mutation was identified. The figure
shows a significant QTc difference between LQTS mutation carriers
and index cases without an identified mutation (KCNQ1 (n= 41) versus
genotype-negative (n=61) p= 0.0001, KCNH2 (n=20) versus genotype-
negative p=0.01, SCN5A (n=10) versus genotype-negative p=0.005).
The scatter dot plot show QTc mean and SD.Molecular genetic analysis
In total, a mutation was identified in 103 of the 200
(52%) index patients (Table 2).
Sequence analysis of the LQTS-associated genes
revealed a pathogenic mutation in 98 of the 200 index
patients. Furthermore, the MLPA analysis revealed 2 dif-
ferent CNVs in KCNH2 (exon 2 dup, and exon 9–10 del)
in two patients, and the RYR2 screening revealed a patho-
genic mutation in 3 of the 36 selected patients (8%).
Mutations in the KCNQ1 gene were most prevalent (58%),
followed by KCNH2 (24%), SCN5A (13%), RYR2 (3%),
KCNE1 (1%) and KCNE2 (1%). Among the 103 mutation-
positive patients, 99 had a single heterozygous mutation,
whereas four female patients (4%) carried multiple muta-
tions (KCNQ1 c.1893dup; QTc 512 ms, KCNE1 p.R32H;
QTc 447 ms, KCNQ1 p.P73T, SCN5A p.V411M; QTc 464
ms and KCNQ1 p.Y111C, SCN5A p.A29V; QTc 490ms);
two homozygous and two compound heterozygous muta-
tion carriers (Table 2). None of the patients hosting
double mutations displayed the phenotype of Jervell and
Lange-Nielsen syndrome with clinical deafness, even
though the mutations resided on different alleles.
The 103 genotype-positive patients stemmed from 64
distinct mutations, the majority of which were observed
in a single case (n=51). Of the 13 mutations that were
observed more than once, the six most common were
KCNQ1 p.Y111C (n=20), KCNQ1 p.R518* (n=6), SCN5A
p.V411M (n=4), SCN5A c.4519_4527del (n=4), KCNQ1
p.Q530* (n=3), and KCNQ1 c.572_576del (n=3).
Approximately one-third (28%) of the mutations had
never previously been reported in LQTS at the time of de-
tection, and were thus novel to this Swedish cohort. These
include seven mutations in KCNQ1, nine in KCNH2 and
two in SCN5A (Table 2). None of these mutations were
observed in 100 analysed population-matched control
Table 2 Pathogenic mutations in the KCNQ1, KCNE1, KCNH2, KCNE2, SCN5A and RYR2-genes among Swedish index
cases referred for genetic testing with respect to LQTS
Gene Exon Nucleotide change Amino acid change Mutation type Region No. of probands Reference
KCNQ1 1 c.217C>A p.P73T Missense N-term 1b Kapplinger et al. 2009
1 c.332A>G p.Y111C Missense N-term 20b Splawski et al. 2000
3 c.506C>G p.T169R Missense S2 1c This studya
3 c.509A>G p.E170G Missense S2-S3 1 This studya
3 c.572_576del p.R192Cfs91* Frame shift S2-S3 3 Tyson et al. 1997
4 c.643G>A p.V215M Missense S3 1 Napolitano et al. 2005
4 c.674C>T p.S225L Missense S4 2 Priori et al 1999
5 c.727C>T p.R243C Missense S4-S5 2 Franqueza et al.1999
5 c.734G>T p.G245V Missense S4-S5 1 This studya
7 c.935C>T p.T312I Missense Pore 1 Wang et al. 1996
7 c.944A>G p.Y315C Missense Pore 1 Splawski et al. 1998
7 c.973G>T p.G325W Missense S6 1 This studya
7 c.973G>A p.G325R Missense S6 2 Tanaka et al. 1997
7 c.1023_1024delinsTT p.L342F Missense S6 1 Donger et al. 1997
7 c.1031C>A p.A344E Missense S6 1 Tester et al. 2005
8 c.1033-1G>C splice Splice site S6 1 This studya
8 c.1046C>G p.S349W Missense C-term 1 Splawski et al. 2000
8 c.1066_1071del p.Q356_Q357del Deletion C-term 1 Liang et al. 2003
10 c.1265delA p.K422Sfs*10 Frame shift C-term 1 Kapplinger et al. 2009
12 c.1552C>T p.R518* Nonsense C-term 6 Wei et al. 2000
12 c.1588C>T p.Q530* Nonsense C-term 3 Tranebjærg et al. 1999
13 c.1615C>T p.R539W Missense C-term 1 Chouabe et al.1997
13 c.1664G>A p.R555H Missense C-term 1 Lupoglazoff et al. 2004
14 c.1697C>T p.S566F Missense C-term 1 Splawski et al. 2000
15 c.1766G>A p.G589D Missense SAR 1 Piippo et al. 2001
15 c.1772G>A p.R591H Missense SAR 1 Neyroud et al. 1999
15 c.1780C>T p.R594* Nonsense SAR 1 This studya
15 c.1781G>A p.R594Q Missense SAR 1 Splawski et al. 2000
16 c.1801C>T p.Q601* Nonsense SAR 1 This studya
16 c.1893dup p.R632Qfs*20 Frame shift C-term 1b Neyroud et al. 1999
KCNH2 2 exon 2 duplication Duplication N-term 1 This studya
2 c.128A>G p.Y43C Missense PAS 1 Napolitano et al. 2005
2 c.157G>A p.G53S Missense PAS 1 Nagaoka et al. 2008
2 c.182A>G p.Q61R Missense PAS 1c This studya
2 c.235_242del p.A79Dfs*63 Frame shift N-term 1 This studya
2 c.244_252dup p.I82_Q84dup Insertion PAC 1 Larsen et al. 2001
2 c.284A>G p.E95G Missense PAC 1c This studya
3 c.453delC p.T152Pfs*14 Frame shift N-term 2 Swan et al. 1999
4 c.526C>T p.R176W Missense N-term 1 Swan et al. 1999
4 c.853_859dup p.D287Gfs*47 Frame shift N-term 1 This studya
5 c.982C>T p.R328C Missense N-term 1 Tester et al. 2005
5 c.1094A>G p.E365G Missense N-term 1 This studya
7 c.1655T>C p.L552S Missense S5 2 Swan et al. 1999
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Table 2 Pathogenic mutations in the KCNQ1, KCNE1, KCNH2, KCNE2, SCN5A and RYR2-genes among Swedish index
cases referred for genetic testing with respect to LQTS (Continued)
7 c.1688G>A p.W563* Nonsense S5 1 Berge et al. 2005
7 c.1706A>G p.Y569C Missense S5 1 This studya
7 c. 1750G>A p.G584S Missense S5 1 Swan et al. 1999
9 c.2254C>T p.R752W Missense cNBD 1 Splawski et al. 2000
9 c.2312A>G p.H771R Missense cNBD 1 This studya
10 c.2453C>T p.S818L Missense cNBD 1 Berthet et al. 1999
9-10 exon 9-10 deletion Deletion cNBD/C-term 1 This studya
12 c.2959_2960del p.L987Vfs*131 Frame shift C-term 2 Splawski et al. 2000
13 c.3107dupG p.D1037Rfs*82 Frame shift C-term 1 Berthet et al. 1999
SCN5A 2 c.86C>T p.A29V Missense N-term 1b This studya
7 c.715A>G p.I239V Missense DI-S4/S5 1 Fodstad et al. 2004
10 c.1231G>A p.V411M Missense DI-S6 4bc Tester et al. 2005
22 c.3893C>T p.P1298L Missense DIII-S4 1 This studya
23 c.4000A>G p.I1334V Missense DIII-S4/S5 1 Kapplinger et al. 2009
26 c.4519_4527del p.Q1507_P1509del Deletion DIII-DIV 4 Keller et al. 2003
28 c.4877G>C p.R1626P Missense DIV-S4 1 Napolitano et al. 2005
28 c.5350G>A p.E1784K Missense C-term 1 Wei et al. 1999
KCNE1 4 c.95G>A p.R32H Missense Extracellular 1b Splawski et al. 2000
KCNE2 2 c.170T>C p.I57T Missense Transmembrane 1 Abbott et al. 1999
RYR2 44 c.6737C>T p.S2246L Missense Cytoplasmatic loop 2c Priori et al. 2001
101 c.14553C>A p.F4851L Missense TM domain 1 Hayashi et al. 2009
a Denotes a novel variant, unique to this cohort. b Compound heterozygous or homozygous mutations c de novo mutation.
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p.P1298L, none were present in any of the large whole
exome sequencing projects “1000 genomes project” or
“NHBLI exome sequencing project (ESP)”. The putative
mutation SCN5A p.P1298L was referred to as rs28937319
in dbSNP with unknown allele frequency and status prob-
able-pathogenic. Although it has been associated with sick
sinus syndrome [25], it has never been reported previously
in LQTS patients, and is thus considered a novel LQTS
mutation.
Evaluation of the pathogenicity in seven of the novel
mutations was straightforward, including two stop muta-
tions (KCNQ1 p.R594*, and KCNQ1 p.Q601*), two frame-
shift mutations resulting in premature stops (KCNH2
p.A79Dfs*63, and KCNH2 p.D287Gfs*47), two CNVs in
KCNH2 as described above, and one splice mutation in
position IVS-1 (KCNQ1 c.1033-1G>C). For the eleven
novel missense variants, the most important factor in de-
termining the pathogenicity was the degree to which a
missense change was conserved in orthologs and in other
proteins with the same domain (Table 3). Phylogenetic
alignments for the novel missense mutations are pre-
sented in Additional file 1, showing that the mutations
affected highly conserved residues. In silico data and co-
segregation are summarised in Table 3. In silico analysisusing SIFT predicted that none of the variants seen would
be tolerated, which is consistent with them being patho-
genic [22]. PolyPhen conservation scores predicted seven
of the variants to be probably damaging and four to be
possibly damaging (Table 3) [23]. In addition, co-
segregation analyses of the novel missense variants were
performed in all families where samples from relatives were
available. The pedigrees showed perfect co-segregation
between the novel sequence variant and the disease in six
families, whereas in four families no interpretation was pos-
sible due to non-penetrant or borderline QTc, and in five
other families there was no samples available or missing
data (data not shown). In the remaining three families, the
variant had occurred de novo.
Among the 64 distinct mutations, missense mutations
were most common (70%), followed by frame-shift muta-
tions (12.5%), nonsense mutations (8%), in-frame dele-
tions/insertions (5%), large deletions/insertions (3%), and
splice-site mutations (1.5%) (Table 4). Most of the 64 dis-
tinct mutations (47%) were localised to the transmembrane
spanning and pore-forming domains, whereas 25% were
localised to the N-terminus, and 28% to the C-terminus.
In 97 of the 200 index patients, no pathogenic muta-
tion was identified. In 19 of these patients rare missense
variants were detected, that could potentially contribute





Region GD SIFT PolyPhen Align-GVGD Segregation
analysis
KCNQ1 3 c.506C>G p.T169R S2 71 not tolerated Possibly damaging C0 de novo
3 c.509A>G p.E170G S2-S3 98 not tolerated Probably damaging C0 Yes
5 c.734G>T p.G245V S4-S5 109 not tolerated Probably damaging C0 Borderline
7 c.973G>T p.G325W S6 184 not tolerated Probably damaging C65 Yes
KCNH2 2 c.182A>G p.Q61R PAS 43 not tolerated Possibly damaging C0 de novo
2 c.284A>G p.E95G PAC 98 not tolerated Probably damaging C0 de novo
5 c.1094A>G p.E365G N-term 98 not tolerated Possibly damaging C0 Yes
7 c.1706A>G p.Y569C S5 194 not tolerated Probably damaging C65 Borderline
9 c.2312A>G p.H771R cNBD 29 not tolerated Probably damaging C25 N/A
SCN5A 2 c.86C>T p.A29V N-term 65 not tolerated Probably damaging C65 Yes
22 c.3893C>T p.P1298L DIII-S4 98 not tolerated Possibly damaging C65 N/A
GD, Grantham distance ordered from largest difference (GD=215) between the substituted amino acids to no difference (GD=0); SIFT, sorting intolerant from
tolerant; PolyPhen, Polymorphism Phenotyping predicting variants as probably damaging, possibly damaging or benign; Align-GVGD, Align Grantham variation
and Grantham distance ordered from most likely (C65) to interfere with function to least likely (C0); Segregation analysis: Yes, segregation demonstrated; de novo,
mutation not present in either parent; Borderline, non-penetrant or borderline QTc; N/A, samples not available or missing data.
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to be pathogenic by themselves. Additional file 2
describes all identified rare variants in the Swedish co-
hort with a frequency less than 5%, as well as all mis-
sense substitutions, all of which were classified as
normal genetic variants.Table 4 Summary of population screening studies of long QT
Splawski
et al. 2000
Number of unrelated index cases (n) 262
Detection rate (%) All cases/more
stringent criteria (*Schwartz score ≥ 4)
51
Novel mutations (%) 60
Multiple mutations (%) -







Mutation type: Missense (%) 72
Nonsense (%) 6
In-frame ins/del (%) 5
Frame shift (%) 10
Splice site (%) 7
Large ins/del (%) -
Mutation region: N-terminal (%) 22
Transmembrane (%) 54
C-terminal (%) 24Genetic cascade screening in family members
In the 103 unrelated families where a LQTS or CPVT
disease-causing mutation was identified, a total of 481
relatives have undergone cascade genetic testing. Of
these relatives, 199 (41%) were mutation carriers, while
282 (59%) did not carry a mutation. The mean numbersyndrome
Tester et al. 2005









541 430 169 2500 200
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included). In total, 5 of the 105 (5%) identified mutations
had occurred de novo in the index patient (four LQTS
mutations and one CPVT mutation, KCNQ1 p.T169R,
KCNH2 p.E95G, KCNH2 p.Q61R, SCN5A p.V411M, and
RYR2 p.S2246L, see Table 2). However, since both par-
ents were not tested in all families, it is possible that this
number is higher (data not shown). In one of the fam-
ilies with a de novo mutation (SCN5A p.V411M), two
children but none of the parents were carriers, indicat-
ing possible germ-line mosaicism.
Discussion
In this study, we have determined the mutation pano-
rama in a Swedish cohort referred for genetic LQTS
testing as part of ordinary health care. Between March
2006 and October 2009, the department of Clinical Gen-
etics in Umeå was to our knowledge the only laboratory
in Sweden screening the LQTS genes. Among the 200
index patients, 64 different mutations were identified in
103 patients (52%); of which 58% occurred in KCNQ1,
24% in KCNH2, 13% in SCN5A, 3% in RYR2, 1% in
KCNE1, and 1% in KCNE2. Thirteen of the mutations
were found in more than one family, whereas 51 oc-
curred only once. Among these mutations, 28% were
novel at the time of detection, and had thus never been
reported previously.
LQTS founder mutations
Two of the recurring mutations, KCNQ1 p.Y111C and
KCNQ1 p.R518*, were identified in 26 of the 103 cases,
thus accounting for approximately 25% of the mutations
in the Swedish LQTS population. We have recently
shown that family members carrying these mutations
share a common haplotype that is specific for each mu-
tation [26] [Abstract number 154:Winbo A. Stattin E.L.
Nordin C. Persson J. Diamant U.B. Jensen S.M. Rydberg
A. Origin, genotype and clinical phenotype of the Long
QT Syndrome R518X/KCNQ1 mutation in Sweden. Pre-
sented at the 46th Annual Meeting of the Association
for European Paediatric and Congenital Cardiology
(AEPC), May 23–26 2012 in Istanbul]. The mutation
KCNQ1 p.Y111C was introduced and enriched in the
Ångerman River valley approximately 600 years ago
[26]. Functional in-vitro studies have demonstrated that
it is a “malignant” mutation with a strong dominant-
negative effect, causing disturbed function of the wild-
type ion channel [27,28]. In contrast to these findings,
we recently showed that the KCNQ1 p.Y111C mutation
presents with a low incidence of life threatening events
in a Swedish Y111C-positive LQTS population [29]. Fur-
thermore, we showed that p.Y111C is a founder muta-
tion in this population [26], a finding which also
contrasts to in vitro-data indicating it to be a malignantmutation. One explanation for these discrepancies could
be the presence of population-specific modifiers, genetic
or other, such as the recently described polymorphisms
in the 3’-UTR of KCNQ1, mitigating the effect of the
mutated allele by reduced expression [30]. Possibly, one
or several of these polymorphisms could exert its attenu-
ating effect through the creation of a novel miRNA-
binding site, a theory that has been proposed for other
disorders where large differences in phenotypic expres-
sion occur [31].
The mutation KCNQ1 p.R518* has previously been
reported in several populations [32,33], as well as a
founder mutation in Sweden [34] and Norway [16], al-
though Berge et al. did not report any founder muta-
tions in the more recent Norwegian LQTS population
survey [8]. A strong founder effect has been described
in the Finnish population [17]. In our study, we identi-
fied three of the Finnish founder mutations (KCNQ1
p.G589D, KCNH2 p.R176W, and KCNH2 p.L552S), as
well as the two common Norwegian mutations (KCNQ1
p.R518* mentioned above, and KCNQ1 p.Q530*) in
several of the patients [16,35].
LQTS genotype-negative index cases
According to published studies, approximately 25% of
index cases with the clinical phenotype of LQTS remain
genotype-negative after comprehensive assessment of
the three most common LQTS genes (KCNQ1, KCNH2,
and SCN5A) [12,13,15]. In this study, 102 index patients
(51%) referred for LQTS testing were negative after se-
quencing of the KCNQ1, KCNH2, KCNE1, KCNE2 and
SCN5A genes. As in any molecular genetic study of dis-
ease, there is a possibility that these individuals have
mutations missed due to technical limitations (e.g.
DHPLC), or located in regions not included in the ana-
lysis; such as in the gene promotors or introns of the
genes chosen for study, or in another LQTS-associated
gene. However, these patients had a significantly shorter
QTc, and reported family history than the mutation car-
riers, and some of them might therefore be suspected of
not having LQTS (Figure 1, Table 1). Several publica-
tions indicate that patients suspected of having LQTS
may actually have CPVT, [8,9,36] and that can be con-
firmed also in the present study. Among 36 genotype-
negative index patients selected for RYR2 screening
based on a history of arrhythmia, aborted cardiac arrest
and/or syncope and/or a family history of SCD, we iden-
tified a disease-causing mutation in 8%. Tester et al.
evaluated the prevalence of RYR2 mutations in a cohort
of patients referred for screening of LQTS genes, identi-
fying mutations in RYR2 among 6% of the 269 genotype-
negative patients [9]. Berge et al. identified mutations in
RYR2 in 17% of the 41 genotype-negative index patients
referred for LQTS testing [8]. Thus, it is critical to
Stattin et al. BMC Cardiovascular Disorders 2012, 12:95 Page 9 of 12
http://www.biomedcentral.com/1471-2261/12/95recognise CPVT as an important differential diagnosis to
LQTS, and to consider mutation screening of the RYR2
gene in patients who do not have a mutation in one of
the LQTS-associated genes.
The presence of copy number variants (CNVs) within
the LQTS disease genes have also been suggested as an
explanation for the lack of identified mutations [37-39].
Therefore, we performed MLPA analysis of all 200 index
patients, identifying 2 CNVs in the KCNH2 gene. Thus,
the yield of CNVs was 2.0% among the 100 genotype-
negative index patients without an identified mutation in
any of the LQTS genes or RYR2. In the study of Tester
et al. CNVs were found in 4.8% of 42 patients with QTc
duration ≥ 480 ms and/or a Schwartz score ≥ 4 who
were negative for mutations in 12 of the LQTS-
associated genes [40]. Eddy et al. identified CNVs in
11.5% of 26 patients with Schwartz score ≥ 4 who were
negative for mutations in the KCNQ1, KCNH2, and
SCN5A genes [38]. Barc et al. identified CNVs in 3.2% of
93 patients with Schwartz score ≥ 3 who were negative
for mutations in the KCNQ1, KCNH2, and SCN5A genes
[39]. These findings suggest that CNVs might be a more
frequent cause of LQTS than mutations in all of the less
common LQTS-associated genes (ANKB, KCNE1,
KCNE2, KCNJ2, CACNA1C, CAV3, SCN4B, AKAP9, and
SNTA1) together [38-40]. Thus, it is important to con-
sider MLPA analysis in patients who do not possess a
mutation in one of the most common LQTS-associated
genes.
Genetic cascade screening in family members
A total of 481 relatives in the 103 families with an iden-
tified mutation have participated in genetic cascade
screening, of which 41% were found to be mutation car-
riers, and 59% were not carriers. Thus, 2.9 (302/103)
individuals per family carried a mutation and were
thereby at risk for LQTS-associated symptoms and SCD.
This finding is lower than the result in Norway, where,
4.7 (305/66) patients per family carried a heterozygote
mutation [8]. In contrast to Imboden et al. [41] no fe-
male predominance among mutation carriers and no
non-random inheritance, with a significant greater num-
ber of affected than expected, could be observed in this
cohort.
This study compared with other population surveys
In the five largest LQTS population surveys that have
been published to date, involving the five most common
LQTS-causing genes (KCNQ1, KCNH2, SCN5A, KCNE1
and KCNE2), the mutation yield was 72%, 51%, 50%,
36%, and 32%, respectively (Table 4) [8,12-15]. In two of
the studies, when using more stringent criteria (i.e.
Schwartz score ≥ 4), the mutation detection rate was
raised from 50% to 72%, and from 32% to 71%,respectively [8,13]. In this study, we obtained a mutation
detection rate of 52%, which lies in the range of the
other population studies. Among individuals with a def-
inite prolonged QTc, 77% carried a mutation, which is in
line with the two studies using more stringent criteria.
We were not able to categorise all the index patients,
since phenotypic information was not available for all of
the patients.
The largest survey, including 2,500 consecutive, unre-
lated LQTS patients, presented one of the lowest muta-
tion yields of 36%. However, the degree of diagnostic
relevance in the referred patients of that study could not
be evaluated, also due to lack of phenotypic information.
The mutations in the KCNQ1, KCNH2 and SCN5A
genes were distributed over the entire coding regions
and adjacent splice sites. The vast majority were hetero-
zygous missense mutations. The distribution of muta-
tions between the different genes and the type of
mutation concur with findings of the other population
surveys. However, the rate of KCNQ1 mutations is
higher in our study (58%), since both of the Swedish
founder mutations p.Y111C and p.R518* are located in
this gene. Most of the mutations (≈60 %) in the pub-
lished surveys have not been reported previously,
whereas we only identified 28% novel mutations in this
study. It is possible that this lower yield is due to the
more than 10 years of publications of several large LQTS
studies, which suggests that the increase in new LQTS
mutations is beginning to be saturated.
Probands carrying multiple mutations
Patients carrying multiple mutations have been shown
to present with a more severe phenotype compared to
patients carrying only one mutation [19]. In one study,
the compound mutation carriers had longer QTc inter-
vals and a younger age-at-onset compared to patients
with only one mutation [19]. In this study, four of the
103 (4%) genotype-positive patients carried more than
one definitely pathogenic mutation. Two of them were
homozygous for the mutation and two compound het-
erozygote. All of them are female and have a family his-
tory of LQTS. The (homozygous) carrier of the KCNQ1
c.1893dup mutation, had a QTc prolongation of 512 ms;
however, there is no information about any history of
syncope or current treatment with beta-blockers. The
parents of the c.1893dup mutation carrier both carried
the mutation in heterozygous form; the mother had a
QTc of 435 ms while the father has a QTc denoted as
normal (data not shown). The KCNE1 p.R32H (homozy-
gous) mutation carrier, had a QTc of 447 ms, is being
treated with beta-blockers and has not experienced syn-
cope. The parents of the p.R32H mutation carrier were
not available for testing, but hemizygosity of the muta-
tion in the proband was excluded by MLPA (data not
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mutations KCNQ1 p.P73T and SCN5A p.V411M, had a
history of suspected seizures and syncope, and she was
not treated with beta-blockers but with Phenytoin. The
carrier of the (compound heterozygote) mutations
KCNQ1 p.Y111C and SCN5A p.A29V, had a history of
presyncope and a QTc of 490 ms.
In the Norwegian survey, no patients had more than
one definitely pathogenic mutation, whereas Kapplinger
et al. reported 9%, and Tester et al. reported 11%
patients with multiple mutations among the genotype-
positive patients [8,13,14]. In the study of Westenskow
et al. compound mutations were reported in 12% of the
genotype-positive LQTS probands. However, of the 20
probands in their study assigned as having multiple
mutations, over half possessed either the KCNE1
p.D85N or KCNQ1 p.P448R common polymorphism as
the “second hit” [42]. Similarly, Tester et al. reported
SCN5A p.A572D as a mutation in 3 of their patients
[13]. In our study, SCN5A p.A572D was identified in 3
patients, KCNQ1 p.P448R in 3 patients, and KCNE1
p.D85N in 12 patients, all of which were determined to
be non-pathogenic (Additional file 2). In four of the
patients, these variants occurred together with a defin-
itely pathogenic mutation. If we had regarded these as
pathogenic mutations, our yield of multiple mutations
among the genotype-positive patients would have been
8% (8/103) instead of 4%.
Sequence variants of unknown significance -
polymorphisms
Missense mutations are the most frequent form of muta-
tion in the LQTS genes, accounting for about 65-73% of
the mutations in the large LQTS population surveys.
Careful interpretation of identified genetic variants is
important, because a missense variant may or may not
cause an altered/distorted protein and a disease pheno-
type [43]. In this study, several of the index patients
carried rare variants, such as KCNE1 p.D85N, KCNQ1
p.P448R, SCN5A p.A572D, SCN5A p.S1103Y, and SCN5A
p.R1193Q. The possible effect of these missense variants
is difficult to interpret and they are referred to in the lit-
erature as both mutations and functional polymorphisms
[44,45]. Although these variants might contribute to the
phenotype, we did not consider these as disease-causing
mutations by themselves, since careful interpretation of
genetic test results is critical in clinical practice [43].
Limitations of the study
The 200 index cases were almost consecutively included;
we have excluded 27 index cases with other diagnoses
such as Jervell and Lange-Nielsen syndrome, Brugada
Syndrome, short QT syndrome, and healthy individuals
sent for LQTS-screening due to a history of first-degreerelative with SUD. No selection of the patients was per-
formed, resulting in a cohort that ranges from low suspi-
cion of LQTS to high. Since the patients were referred
for LQTS screening in ordinary health care, the clinical
data were collected retrospectively and is thus not
complete for all families. Only 23 of 105 exons (8–15,
44–50, 83, 88–105) of the gene RYR2 were analysed.
DNA was not available for screening of all five genes in
some of the individuals, and therefore it is possible that
some double mutations might have been missed. Due to
the lack of DNA, there were incomplete analyses of the
KCNQ1 gene in three individuals, in the KCNH2 gene in
two, KCNE1 in five, KCNE2 gene in four, and in the
SCN5A gene in nine individuals. For the same reason
MLPA was not performed in two cases.Conclusions
The distribution of mutations between the different
genes, as well as the type of mutation, concur with find-
ings of other LQTS population surveys. In contrast, the
mutation panorama in this Swedish cohort is charac-
terised by two founder mutations in the KCNQ1 gene
that accounts for one-fourth of the identified mutations.
The findings of a mutation in RYR2 among 8% of the
selected cases, as well as CNVs among 2% of all
genotype-negative cases suggest that mutation analysis
of RYR2 and MLPA analysis in a genotype-negative
LQTS population is of importance and might give a
higher yield than screening of the less common LQTS-
associated genes.Additional files
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